Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAR 001

Next Previous
X
Search
Drug Profile

CAR 001

Alternative Names: CAR BiTE γδT; CAR-001; CD3ε Nb-BiTE; Nb-CAR.BiTE-γδT PD-L1

Latest Information Update: 21 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ever Supreme Bio Technology
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action Immunologic cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 29 Nov 2023 Ever Supreme Bio Technology plans a phase I/IIa CAR001 trial for Solid tumors (Second-line therapy) in Taiwan (IV, Infusion) (NCT06150885)
  • 21 Sep 2023 Preclinical trials in Solid tumours in Taiwan (Parenteral)
  • 21 Sep 2023 Ever Supreme Biotechnology files an IND application with the US FDA in the US for Solid tumors

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top